Literature DB >> 28765734

Long-Term Outcome of Kawasaki Disease Complicated by a Large Coronary Aneurysm.

Jo Won Jung1.   

Abstract

Entities:  

Year:  2017        PMID: 28765734      PMCID: PMC5537144          DOI: 10.4070/kcj.2017.0135

Source DB:  PubMed          Journal:  Korean Circ J        ISSN: 1738-5520            Impact factor:   3.243


× No keyword cloud information.
Refer to the page 516-522 Kawasaki disease was first identified in Japan by Tomisaku Kawasaki in 1967,1) and has now been described worldwide. In Korea, the annual incidence of KD was 194.7 per 100000 children in 2014, and the coronary aneurysm rate was 1.7%.2) Kawasaki disease (KD) is an acute febrile disease of unknown etiology. It causes systemic inflammation of vessels through the whole body and especially affects coronary arteries in children younger than 5 years of age.3) The disease leads to coronary artery aneurysms in ≈25% of untreated cases. Treatment within 10 days of illness onset with high dose intravenous immunoglobulin (IVIG) and aspirin has proven effective in dramatically reducing the risk of cardiac complications. However, approximately 20% of patients who require a second dose of IVIG for KD do not adequately respond to this treatment and require additional medications such as corticosteroid or infliximab.4)5) The natural history of coronary arterial inflammation in KD was demonstrated to occur through 3 mechanisms (Fig. 1):3)6) 1) no coronary artery changes, 2) mild, transient dilatation that resolves within 4-6 weeks, 3) necrotizing arteritis that forms an aneurysm. Coronary arterial aneurysm can progress to subacute/chronic vasculitis, luminal myofibroblastic proliferation, and laminar non-occlusive thrombosis. Its phenotypes are myocardial infarction, possible progression to a normal luminal dimension, or further progression to complex stenosis with calcification.3)6) In 1% of cases with such damage, diffuse dilatation of the coronary arteries can progress to a giant aneurysm. The progression to giant aneurysm increases the risks of acute thrombosis and long-term myocardial ischemia.7)
Fig. 1

The natural history of coronary arterial inflammation in Kawasaki disease.6) Printed with permission from Elsevier.

The severity of coronary artery luminal lesions determines the risk range for long-term management. Such risk assessment depends on the patient's maximal Z score in any branch by echocardiography or coronary angiography/angio-computed tomography. Large/giant aneurysms are defined as Z score ≥10 or absolute inner diameter ≥8 mm, and medium aneurysms are those with a Z score ≥5 to <10 or an absolute inner diameter <8 mm.3)5) The treadmill exercise test is the least sensitive method to detect myocardial ischemia in patients with KD.8) Stress myocardial scintigraphy has been shown to be useful for risk stratification.8) In data of 76 Japanese patients with giant aneurysm of diameter ≥8.0 mm from 1972 to 2011,8) 46 (61%) underwent catheter and surgical coronary interventions, and 12 showed acute myocardial infarction. Of all patients, 7 died and 1 underwent a heart transplantation, resulting in 95%, 88%, and 88% survival rates at 10, 20, and 30 years after the onset of KD, respectively. The giant aneurysm was located in the right coronary artery only in 17 patients, left coronary artery only in 13 patients, and both coronary arteries in 46 patients. Although one patient with chest discomfort showed 99% stenosis of the left anterior descending artery in cardiac catheterization, his treadmill exercise stress test did not show ischemic changes on electrocardiogram. Korean nationwide data collected between 1990 and 2011 was reviewed by Jang et al.9) and showed 239 patients with coronary aneurysms of diameter >6 mm. Severe stenosis or occlusion of the coronary artery were analyzed, and percutaneous transluminal coronary balloon angioplasty was performed in 10 patients, stent placement in 9 patients, and percutaneous transluminal coronary rotational ablation in 3 patients. Thirteen patients presented with suggestive myocardial infarction, 14 patients underwent coronary artery bypass graft surgery, and 5 patients died during the follow-up period. A Korean study of long-term prognosis for 71 patients with KD complicated by a coronary aneurysm from 1986 to 2013 was compared between coronary aneurysms sized 6-8 mm and those ≥8 mm. Myocardial infarction only occurred in 7 patients with coronary aneurysm ≥8 mm in diameter, and the median elapsed time from KD onset to myocardial infarction was 4.0 months (range: 0.5-31.2 months). Despite the loss of one patient, there was no statistical difference in the cumulative coronary intervention rate for the two groups of patients with aneurysm.10) For KD patients with giant coronary aneurysm, careful planning of follow-up is mandatory for long-term manage, and aggressive treatments with transcatheter or surgical intervention are needed.
  9 in total

1.  Cardiac Complications, Earlier Treatment, and Initial Disease Severity in Kawasaki Disease.

Authors:  Joseph Y Abrams; Ermias D Belay; Ritei Uehara; Ryan A Maddox; Lawrence B Schonberger; Yosikazu Nakamura
Journal:  J Pediatr       Date:  2017-06-12       Impact factor: 4.406

2.  Nationwide survey of coronary aneurysms with diameter >6 mm in Kawasaki disease in Korea.

Authors:  Gi Young Jang; I-seok Kang; Jae Young Choi; Eun Jung Bae; Young-Hwue Kim; Seong Ho Kim; Jae Sook Ma
Journal:  Pediatr Int       Date:  2015-01-16       Impact factor: 1.524

3.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

Review 4.  Kawasaki disease--the importance of prompt recognition and early referral.

Authors:  Daniel Golshevsky; Michael Cheung; David Burgner
Journal:  Aust Fam Physician       Date:  2013-07

5.  Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014.

Authors:  Gi Beom Kim; Sohee Park; Lucy Youngmin Eun; Ji Whan Han; Soo Young Lee; Kyung Lim Yoon; Jeong Jin Yu; Jong-Woon Choi; Kyung-Yil Lee
Journal:  Pediatr Infect Dis J       Date:  2017-05       Impact factor: 2.129

Review 6.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Authors:  Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

7.  Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms: a single-institution experience.

Authors:  Kenji Suda; Motofumi Iemura; Hiroshi Nishiono; Yozo Teramachi; Yusuke Koteda; Shintaro Kishimoto; Yoshiyuki Kudo; Shinichi Itoh; Haruka Ishii; Takafumi Ueno; Tadashi Tashiro; Masakiyo Nobuyoshi; Hirohisa Kato; Toyojiro Matsuishi
Journal:  Circulation       Date:  2011-04-18       Impact factor: 29.690

8.  Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.

Authors:  Yun Ju Lim; Jo Won Jung
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

9.  Long-Term Prognosis for Patients with Kawasaki Disease Complicated by Large Coronary Aneurysm (diameter ≥6 mm).

Authors:  Ji Seok Bang; Gi Beom Kim; Bo Sang Kwon; Mi Kyung Song; Hyo Soon An; Young Whan Song; Eun Jung Bae; Chung Il Noh
Journal:  Korean Circ J       Date:  2017-07-27       Impact factor: 3.243

  9 in total
  2 in total

1.  Risk factors for the occurrence and persistence of coronary aneurysms in Kawasaki disease.

Authors:  Soo-Kyeong Jeon; Geena Kim; Hoon Ko; Joung-Hee Byun; Hyoung Doo Lee
Journal:  Korean J Pediatr       Date:  2018-11-22

2.  Out-of-hospital cardiac arrest in a young adult survivor with sequelae of childhood Kawasaki disease: A case report.

Authors:  Ke-Fu Zhu; Li-Jiang Tang; Shao-Ze Wu; Yi-Min Tang
Journal:  World J Clin Cases       Date:  2019-11-06       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.